CAS 220347-05-7: (1S,2R,3S,4R)-4-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)cyclopentane-1,2,3-triol

Applications Labelled Deshydroxyethoxy Ticagrelor analog of Ticagrelor (T437700) an antiplatelet agent, and preventative in the treatment of heart attacks, myocardial infarction, and other pulmonary diseases. References Zhang, H. et al.: Bioorg. Med. Chem. Lett., 22, 3598 (2012);

Applications Deshydroxyethoxy Ticagrelor analog of Ticagrelor (T437700) an antiplatelet agent, and preventative in the treatment of heart attacks, myocardial infarction, and other pulmonary diseases. References Zhang, H. et al.: Bioorg. Med. Chem. Lett., 22, 3598 (2012);

Deshydroxyethoxy Ticagrelor is a metabolite that emerges as a derivative of the antiplatelet medication Ticagrelor. This compound originates from the biotransformation processes in the human body, where Ticagrelor undergoes metabolic conversion. As a metabolite, Deshydroxyethoxy Ticagrelor retains activity, contributing to the parent compound's overall therapeutic effect. The primary mode of action involves the reversible inhibition of the P2Y12 receptor on platelets, which plays a crucial role in the inhibition of platelet aggregation. The applications of Deshydroxyethoxy Ticagrelor are primarily linked to the study of its pharmacokinetic and pharmacodynamic properties to understand better its contribution to Ticagrelor's efficacy and safety profile. Such insights can help refine dosing strategies and therapeutic regimens in clinical settings, enhancing antiplatelet therapy's precision, especially in managing acute coronary syndromes and preventing thrombotic vascular events. Understanding this metabolite is essential for developing next-generation antiplatelet agents and optimizing current treatment protocols.